Hepion Pharma names renowned liver expert, Dr. Stephen Harrison, to its SAB

Dr. Stephen Harrison, a leading authority on liver diseases, has joined the scientific advisory board (SAB) of Hepion Pharmaceuticals (NASDAQ:HEPA).

Dr. Harrison is a visiting professor of hepatology at the Radcliffe Department of Medicine, University of Oxford; as well as the medical director for Pinnacle Clinical Research and the president of Summit Clinical Research.

He is a peer-reviewer for more than 20 medical journals, and has published more than 200 peer-reviewed articles on hepatitis C and non-alcoholic fatty liver disease.

“With his extensive experience in chronic hepatitis and fatty liver disease and non-alcoholic steatohepatitis (NASH), Dr. Harrison joins us at an opportune time, as we prepare for CRV431 to enter the clinic as a potential treatment for NASH and continue to progress its clinical development more broadly in liver disease,” Dr. Carol Brosgart, chairwoman of the Hepion’s SAB, said in a statement.

Previously, Dr. Harrison was a professor of medicine at the Uniformed Services University of the Health Sciences, and an associate editor of Hepatology and Alimentary Pharmacology and Therapeutics. He was a Colonel in the United States Army for 20 years, retiring in 2016.

“I am looking forward to working with the Hepion team to develop CRV431, a promising candidate with the potential to treat not only hepatitis and NASH, but other diseases in which fibrosis plays a role,” Dr. Harrison said.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.